The SToP-BPD study Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants Clinical lesson Oct 2011.

Slides:



Advertisements
Similar presentations
Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomized control trial (BMJ. 2010;341:c5462)
Advertisements

Experience of inhaled nitric oxide in babies with pulmonary hypertension in a tertiary neonatal unit Supriya Bhoomaiah Vishna Rasiah Birmingham Womens.
Safety Reporting IN Clinical Trials
 may be efective in preventing SGA birth in women at high risk of preeclampsia although the effect size is small. (c)
John L. Stefano MD Professor of Pediatrics Jefferson Medical College Section Chief, CCHS Division of Neonatology.
Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
(Pediatrics 2007;e20-e28) 1. Medical End of Life decisions was defined as medical decisions with the effect or the probable effect that death was hastened.
Medication program guideline How to use the medication program – First Administration – Dosage lowering after hypertension – Print function.
Drug Utilization Review (DUR)
Clinical Trials Hanyan Yang
Case Report Form Start-up Meeting March 25, 2010 Kingston, ON.
Dose-Toxicity Study of Oral Prednisone in Ocular Myasthenia Michael Benatar, Mike McDermott, Gil Wolfe and Don Sanders.
Trial Procedures and Forms
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients A Randomized Trial Journal Club 09/01/11 JAMA, February 4, 2009—Vol 301, No
Dr.Zhila Abedi Asl MD.Fellowship of lnfertility Tehran medical university.
6th June 2004 By Norah A A Al Khathlan M.D. JOURNAL CLUB A Comparison of High-Dose and Standard-dose Epinephrine in Children with Cardiac Arrest NEJM 350;17April.
ASCO Presentation Summary: Chemotherapy Treatment Plan and Summary Templates as a Component of Comprehensive Cancer Care Kansas Cancer Partnership University.
Discrete Probability Distributions
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Sarah Struthers, MD March 19, 2015
Treatment for Adolescents With Depression Study (TADS)
MEDICATION ERROR PURPOSE / POLICY Purpose: To provide a process for identifying, reporting, and reviewing medication errors Policy: Any med error will.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
CHEST. 2007;131(4): Methylprednisolone Infusion in Early Severe ARDS - Results of a Randomized Controlled Trial.
Audit of RBC Transfusion in Premature Infants 2001 Dr Ho Hing Tung (Paediatrics) Dr Sherman Lee (Clinical Audit) Dr Raymond Chu (Haematology) Pamela Youde.
An interdisciplinary approach to care of infants with bronchopulmonary dysplasia. Alfred L. Gest, MD.
Evidence Based Medication Use in the NICU: Erythropoietin Dan Ellsbury MD Director, Continuous Quality Improvement Pediatrix Medical Group.
Position of equipoise on ‘when to start’ IUGR babies with AREDFV on antenatal Dopplers do have an increased risk of NEC BUT…no evidence that delaying.
The ADEPT Study Study Management
The Diabetic Retinopathy Clinical Research Network Protocol I: Clinical Applications Supported through a cooperative agreement from the National Eye Institute.
Clinical Experience With Antibiotic Protocol & RSD N=22 Duration of treatment: 2-4 months Retrospective, open label, clinical trial Responses are based.
Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.
TEMPLATE DESIGN © Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to COPD.
1 Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti- Infective Drug Advisory Committee Hugo.
Steroid Use in Acute Exacerbations of COPD Katherine Kielts, Pharm.D. PGY2 Critical Care Resident St. Vincent Indianapolis Hospital September 17, 2015.
Eric S. Shinwell, MD Kaplan Medical Center Rehovot Hebrew University Jerusalem, Israel Postnatal Steroids 2005.
The SToP-BPD study Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants Initiation visit.
UOG Journal Club: July 2011 Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized,
Guideline for Metropolitan Paediatric Wards & Emergency Departments 1st edition Humidified High Flow Nasal Cannula Oxygen.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
RAD Immunosuppression in Heart Transplant Recipients Duke Heart Failure Research Pager:
Jessica Gosney 25 th February * Background * Aims * Methods * Standards * Results * Discussion * Recommendations.
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
MCH Research Roundtable: Early Cortisol Replacement to Prevent BPD Grant MCJ Kristi L. Watterberg, M.D.
LSU Journal Club Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia A Systematic Review and Meta-analysis Scott Hebert,
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Barbara Schmidt, Kristine Sandberg Knisely Chair in Neonatology
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
CLINICAL PROTOCOL DEVELOPMENT
Enrolling in Clinical Trials
Alcohol, Other Drugs, and Health: Current Evidence
Correlation of developmental outcome with severity of bronchopulmonary dysplasia in extremely low gestational age neonates Karen Belen, Chengqiu Lu, Narges.
*Continue on SAE supplemental page CTT21 A if more space is required
Protocol Review July 8, 2016 Katie Oldmixon, RN MGH DCC
Protocol Review July 8, 2016 Katie Oldmixon, RN MGH DCC
Patient-Ventilator System Checks
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
Corticosteroids in the ICU
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
The efficacy and safety of omalizumab in pediatric allergic asthma
PRESENTER: Quynh vu, pgy-2
Minimizing Lung Injury Homeroom Driver Diagram
Presentation transcript:

The SToP-BPD study Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants Clinical lesson Oct 2011

History of steroids in neonatology

The Evidence EC Eichenwald, AR Stark; Arch. Dis. Child. Fetal Neonatal Ed. 2007;92;

Furthermore… Consequence of publications on adverse neurological sequelae: late and low doses dexa Current policy Amsterdam: 1.4 mg/kg cumulative dose

Hydrocortison Netherlands: 4 centra administer hydrocortison, 6 dexa in low doses HC: No prospective studies on risk:benefit ratio Retrospective studies –No adverse effects neurological outcome (no placebogroup) –Case control compared to dexa no decreased effect fot the lungs

Equipoise! Therefore, it is time for a nwe trial

Objective of the study Investigate is hydrocortisone, initiated d after birth, reduces the combined outcome of death or BPD at 36 wks PMA Investigate if a possible beneficial effect on BPD is not with (unacceptable) increased adverse effects

Inclusion criteria GA < 30 wks and/or BW < 1250 g Ventilator dependent between 7-14 d PNA RI (MAwP x FiO2) ≥ 3.5

Exclusion criteria Chromosomal abnormalities Congenital pulmonary abnormalities Congenital neurological abnormalities Steroid treatment prior to inclusion with the purpose to improve the pulmonary function –NB not hypotension

Randomization Possible between 7-14 d PNA Hydrocortison or placebo 22 dg First dose within 24 hr after inclusion Twins can be allocated to the same group –Procedure on the website

Website at (NNRN)

Medication HC course –Hydrocortisone Cumul. dose 72,5 mg/kg (=2.5 mg/kg dexa): 5 mg/kg/d in 4 times for 7 d 3,75 mg/kg/d in 3 times for 5 d 2,5 mg/kg/d in 2 times for 5 d 1,25 mg/kg/d in 1 once daily for 5 d Placebo mannitol as base (pH and Osmol HC) Medication kit contains of 23 vials Totale duration 22 days

Medication program

Study medication Pharmacy prepares medication PDMS configuration Medication per day prepared

Rescue therapy

Treatment failure of vroege rescue Reason for consideration open label rescue: –deterioration with RI>10 for >6 uur –No improvement (RI<10) and: At least 10 dys study medication Failure extubation attempt < 24 hr before starting rescue Rescue with HC according to study schedule and stop study medications

Late rescue treatment Patient still ventilator dependent after 22 d Failed extubation attempt Late rescue possible with HC according to study protocol

Documents for the Nurses Summary (also in French)

Print out Daily reports

Web-based Alert procedure Alert Procedure (automated to should be used Occurrence of a SUSAR Death Simultanousely using indomethacine/ibuprofen and study medication Occurrence of an solitary intestinal perforation Occurrence of hypertension, as defined in protocol Use of open label hydrocortisone Reporting should be done < 72 hr of becoming aware ot the event.

Discharge from level III center Letter for paediatrician on the website (also in French)

Oxygen reduction test Criteria: only defined by O 2 Dependent on saturation targets or other conditions Practical guideline on the website

Questions?